Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA® (lumateperone) as an adjunctive therapy with oral antidepressants for adults with major depressive disorder (MDD). The approval, the first for CAPLYTA® under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc., introduces a novel, well-tolerated treatment option for adults with depression who experience persistent symptoms despite current antidepressant therapy. CAPLYTA® demonstrated superior efficacy, with early symptom improvement, and a favorable safety profile consistent with its prior indications in schizophrenia and bipolar depression. The once-daily oral therapy requires no dose titration and is associated with minimal weight gain, metabolic impact, or sexual side effects, addressing key challenges in long-term depression management.
Science Significance
The approval is supported by two pivotal Phase 3 studies (501 and 502) showing that CAPLYTA®, when added to standard antidepressants, produced statistically significant and clinically meaningful improvement in depressive symptoms, as measured by the Montgomery–Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression–Severity (CGI-S) scores. A large separation from placebo was observed in both trials — −4.9 points in Study 501 (effect size 0.61) and −4.5 points in Study 502 (effect size 0.56) — with improvement seen as early as one week. In the six-month open-label extension (Study 503), 80% of patients achieved response and 65% reached remission, underscoring CAPLYTA®’s potential to deliver durable outcomes. Although its exact mechanism is not fully understood, CAPLYTA® exhibits high serotonin 5-HT2A receptor occupancy and moderate dopamine D2 receptor binding, a dual activity thought to balance efficacy with tolerability. This multimodal pharmacology may represent a new paradigm for adjunctive antidepressant therapy, addressing both mood and cognitive symptoms of MDD.
Regulatory Significance
The FDA approval extends CAPLYTA®’s portfolio to four indications, covering major depressive disorder, bipolar I and II depression (as monotherapy and adjunctive therapy), and schizophrenia. This milestone reinforces the FDA’s continued support for neuroscience innovation and multi-indication expansion of well-characterized therapies. By enabling adjunctive use alongside existing antidepressants, the agency recognizes CAPLYTA® as a complementary, rather than replacement, therapy, aligning with modern personalized approaches to psychiatric care. The decision follows extensive evaluation of long-term safety data, which confirmed that CAPLYTA®’s metabolic, cardiovascular, and neurological profiles were comparable to placebo. No new safety concerns were identified, and rates of extrapyramidal symptoms and sexual side effects remained low. The FDA’s decision thus reflects growing regulatory confidence in next-generation antipsychotics with improved tolerability, offering clinicians greater flexibility in treating resistant depression.
Business Significance
Advertisement
The CAPLYTA® approval marks Johnson & Johnson’s first FDA milestone since its acquisition of Intra-Cellular Therapies, reinforcing its leadership in the neuropsychiatric therapeutics market. The drug’s expansion into MDD — one of the largest unmet needs in mental health — is expected to significantly broaden its commercial reach. Major depressive disorder affects about 22 million U.S. adults, and nearly two-thirds of patients fail to achieve remission with current antidepressants. CAPLYTA®’s differentiated safety and efficacy profile positions it as a first-choice adjunctive option, potentially redefining treatment algorithms. According to Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience at J&J Innovative Medicine, “CAPLYTA® has the potential to become a new standard of care across major mental health disorders, setting a new expectation for remission as the goal, not just response.” This regulatory success also strengthens J&J’s neuroscience portfolio ahead of its supplemental NDA for relapse prevention in schizophrenia, further consolidating its investment in precision mental health innovation.
Patients’ Significance
For millions living with major depressive disorder, the FDA approval of CAPLYTA® offers renewed hope for achieving remission — not merely symptom reduction. In trials, patients experienced early and sustained improvement in mood, energy, and cognitive function without the side effects that often force discontinuation. “Adding CAPLYTA® may help patients achieve lasting wellness and regain quality of life,” said Roger S. McIntyre, M.D., FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto. The Depression and Bipolar Support Alliance (DBSA) echoed this sentiment, emphasizing the therapy’s role in broadening patient choice and reducing the burden of treatment-resistant depression. Because CAPLYTA® requires no titration, it simplifies initiation and adherence — a critical factor for patients navigating complex medication regimens. The medication’s consistent efficacy and minimal metabolic effects further support long-term use and sustained recovery.
Policy Significance
The approval reinforces federal and industry efforts to modernize mental health treatment frameworks, particularly in response to persistent unmet needs in depression care. By approving a novel adjunctive agent with proven real-world tolerability, the FDA continues its trend of encouraging multi-mechanistic treatments that address complex psychiatric pathophysiology. It also underscores a policy emphasis on reducing the societal and economic burden of depression, estimated to be one of the leading causes of disability in the U.S. J&J’s development and submission of CAPLYTA® under a supplemental NDA framework further demonstrate the effectiveness of adaptive regulatory pathways that leverage existing safety data to accelerate innovation. As mental health remains a public health priority, CAPLYTA®’s approval could guide future regulatory strategies for adjunctive and multi-indication psychiatric therapies, ensuring faster access to safe, evidence-based treatments.
Transaction Highlights
FDA approval of CAPLYTA® (lumateperone) as adjunctive therapy for adults with MDD is based on two successful Phase 3 trials (501 and 502) and a six-month open-label extension confirming durable efficacy and tolerability. The therapy demonstrated early symptom relief, consistent metabolic safety, and 65% remission at six months. This marks Johnson & Johnson’s fourth CAPLYTA® indication, expanding its neuropsychiatric footprint while addressing the two-thirds of patients who remain symptomatic on standard antidepressants. CAPLYTA®’s once-daily dosing, no titration, and placebo-comparable metabolic impact position it as a transformative, accessible therapy for patients and prescribers alike.
Source: Johnson & Johnson Press Release
